BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 17510207)

  • 21. Phase I and pharmacokinetic trial of the novel taxane BMS-184476 administered as a 1-hour intravenous infusion in combination with cisplatin every 21 days.
    Sun W; Stevenson JP; Gallagher ML; Vaughn D; Hahn SM; Haller DG; Cohen M; Kopit J; Gallant G; O'Dwyer PJ
    Clin Cancer Res; 2003 Nov; 9(14):5221-7. PubMed ID: 14614002
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase I and pharmacokinetic study of polymeric micelle‑formulated paclitaxel in adult Chinese patients with advanced solid tumors.
    Lv F; Cao J; Zhang J; Qian J; Peng W; Sun S; Li W; Zhang W; Guo W; Li J
    Cancer Chemother Pharmacol; 2014 Jun; 73(6):1173-9. PubMed ID: 24658629
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumors.
    Mani S; McDaid H; Hamilton A; Hochster H; Cohen MB; Khabelle D; Griffin T; Lebwohl DE; Liebes L; Muggia F; Horwitz SB
    Clin Cancer Res; 2004 Feb; 10(4):1289-98. PubMed ID: 14977827
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A dose-finding and pharmacodynamic study of bortezomib in combination with weekly paclitaxel in patients with advanced solid tumors.
    Ramaswamy B; Bekaii-Saab T; Schaaf LJ; Lesinski GB; Lucas DM; Young DC; Ruppert AS; Byrd JC; Culler K; Wilkins D; Wright JJ; Grever MR; Shapiro CL
    Cancer Chemother Pharmacol; 2010 May; 66(1):151-8. PubMed ID: 19774377
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I study of oral ridaforolimus in combination with paclitaxel and carboplatin in patients with solid tumor cancers.
    Chon HS; Kang S; Lee JK; Apte SM; Shahzad MM; Williams-Elson I; Wenham RM
    BMC Cancer; 2017 Jun; 17(1):407. PubMed ID: 28595616
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I and pharmacokinetic study of irinotecan and docetaxel in patients with advanced solid tumors: preliminary evidence of clinical activity.
    Adjei AA; Klein CE; Kastrissios H; Goldberg RM; Alberts SR; Pitot HC; Sloan JA; Reid JM; Hanson LJ; Atherton P; Rubin J; Erlichman C
    J Clin Oncol; 2000 Mar; 18(5):1116-23. PubMed ID: 10694565
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I and pharmacokinetic study of sequential paclitaxel and trabectedin every 2 weeks in patients with advanced solid tumors.
    Chu Q; Mita A; Forouzesh B; Tolcher AW; Schwartz G; Nieto A; Soto-Matos A; Alfaro V; Lebedinsky C; Rowinsky EK
    Clin Cancer Res; 2010 May; 16(9):2656-65. PubMed ID: 20406837
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms.
    Sandor V; Bakke S; Robey RW; Kang MH; Blagosklonny MV; Bender J; Brooks R; Piekarz RL; Tucker E; Figg WD; Chan KK; Goldspiel B; Fojo AT; Balcerzak SP; Bates SE
    Clin Cancer Res; 2002 Mar; 8(3):718-28. PubMed ID: 11895901
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase I clinical trial of weekly paclitaxel, weekly carboplatin, and concurrent radiotherapy for primary cervical cancer.
    Rao GG; Rogers P; Drake RD; Nguyen P; Coleman RL
    Gynecol Oncol; 2005 Jan; 96(1):168-72. PubMed ID: 15589596
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I study of paclitaxel poliglumex administered weekly for patients with advanced solid malignancies.
    Mita M; Mita A; Sarantopoulos J; Takimoto CH; Rowinsky EK; Romero O; Angiuli P; Allievi C; Eisenfeld A; Verschraegen CF
    Cancer Chemother Pharmacol; 2009 Jul; 64(2):287-95. PubMed ID: 19034451
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Weekly paclitaxel combined with pegylated liposomal doxorubicin (CaelyxTM) given every 4 weeks: dose-finding and pharmacokinetic study in patients with advanced solid tumors.
    Briasoulis E; Pentheroudakis G; Karavasilis V; Tzamakou E; Rammou D; Pavlidis N
    Ann Oncol; 2004 Oct; 15(10):1566-73. PubMed ID: 15367419
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase I study of a combination of s-1 and weekly paclitaxel in patients with advanced or recurrent gastric cancer.
    Ueda Y; Yamagishi H; Ichikawa D; Morii J; Koizumi K; Kakihara N; Shimotsuma M; Takenaka A; Yamashita T; Kurioka H; Nishiyama M; Morita S; Nakamura K; Sakamoto J
    Oncology; 2005; 69(3):261-8. PubMed ID: 16138002
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A dose escalation study of weekly docetaxel in patients with advanced solid tumors.
    Kouroussis C; Agelaki S; Mavroudis D; Souglakos J; Kakolyris S; Kalbakis K; Vardakis N; Reppa D; Hatzidaki D; Samonis G; Georgoulias V
    Cancer Chemother Pharmacol; 2000; 46(6):488-92. PubMed ID: 11138462
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer.
    Hainsworth JD; Burris HA; Erland JB; Thomas M; Greco FA
    J Clin Oncol; 1998 Jun; 16(6):2164-8. PubMed ID: 9626217
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase I dose escalation and pharmacokinetic study on the nanoparticle formulation of polymeric micellar paclitaxel for injection in patients with advanced solid malignancies.
    Shi M; Sun J; Zhou J; Yu H; Yu S; Xia G; Wang L; Teng Y; Liu G; Yu C; Feng J; Shen Y
    Invest New Drugs; 2018 Apr; 36(2):269-277. PubMed ID: 28868573
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase I study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in solid tumors.
    Khuri FR; Glisson BS; Kim ES; Statkevich P; Thall PF; Meyers ML; Herbst RS; Munden RF; Tendler C; Zhu Y; Bangert S; Thompson E; Lu C; Wang XM; Shin DM; Kies MS; Papadimitrakopoulou V; Fossella FV; Kirschmeier P; Bishop WR; Hong WK
    Clin Cancer Res; 2004 May; 10(9):2968-76. PubMed ID: 15131032
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Weekly paclitaxel and cisplatin with concurrent radiotherapy in locally advanced non-small-cell lung cancer: a phase I study.
    Frasci G; Comella P; Scoppa G; Guida C; Gravina A; Fiore F; Casaretti R; Daponte A; Parziale A; Comella G
    J Clin Oncol; 1997 Apr; 15(4):1409-17. PubMed ID: 9193333
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aggressive simultaneous radiochemotherapy with cisplatin and paclitaxel in combination with accelerated hyperfractionated radiotherapy in locally advanced head and neck tumors. Results of a phase I-II trial.
    Kuhnt T; Becker A; Pigorsch S; Pelz T; Bloching M; Passmann M; Lotterer E; Hänsgen G; Dunst J
    Strahlenther Onkol; 2003 Oct; 179(10):673-81. PubMed ID: 14566475
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A dose-finding study of the weekly administration of paclitaxel in patients with advanced solid tumors.
    Kouroussis C; Kakolyris S; Mavroudis D; Androulakis N; Kalbakis K; Agelaki S; Sarra E; Souglakos J; Christodoulakis M; Samonis G; Georgoulias V
    Am J Clin Oncol; 2001 Aug; 24(4):404-7. PubMed ID: 11474274
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I study of the farnesyltransferase inhibitor lonafarnib with weekly paclitaxel in patients with solid tumors.
    Ready NE; Lipton A; Zhu Y; Statkevich P; Frank E; Curtis D; Bukowski RM
    Clin Cancer Res; 2007 Jan; 13(2 Pt 1):576-83. PubMed ID: 17255280
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.